SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2786Rgen down >20 %: Repligen Reports Phase 2b Results for RG2417 for Bipolar Desjemmeri-3/7/2011
2785Amylin (AMLN) off about 25% as Bydureon fails a non-inferiority trial against Vituck-3/3/2011
2784CARMIEL, Israel, Feb. 25, 2011 /PR Newswire/ -- Protalix BioTherapeutics, Inc. (tnsaf-2/25/2011
2783DCTH on refusal to file. Some people somewhere may have gotten burned since chartom pope-2/22/2011
2782ROSG -25% PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomictnsaf-2/18/2011
2781>>"Speaking of recent financing, DSCO off 23% on another one. Is it etuck-2/16/2011
2780cant count out Mann, i think this may be a good buy for the long term if im not Brasco One-2/14/2011
2779mnkd anyone?mopgcw-2/11/2011
2778My charity portfolio gamble Renovo down 75% on failure of Juvista PIII. (Not henigel bates-2/11/2011
2777Completion of the IDX375 3-day trial was announced at the JPM conference in JanuDewDiligence_on_SI-2/9/2011
2776I toyed with getting out for a modest gain recently. Sorry I did not now. Theytuck-2/9/2011
2775Management credibility is on the line insofar as IDIX was presumably sitting on DewDiligence_on_SI-2/9/2011
2774Idenix (IDIX) off ~25% after hours. Clinical hold removed at the cost of droppituck-2/9/2011
2773vvus is the next pFE! to da moon! oh yeah!!Brasco One-2/2/2011
2772Thanks Rick. Your numbers have more credibility than mine anyday, glad they difffred hayes-2/2/2011
2771Hi, Fred. I expect the middle dose (46 mg topiramate) to have a good chance of scaram(o)uche-2/2/2011
2770Thanks Rick. I was guessing vvus had about a 40 percent chance. Now maybe 20 perfred hayes-2/1/2011
2769He lost a critical edge, for a moment. FDA has been doing a good job, it'scaram(o)uche-2/1/2011
2768Odds have shifted, but thru my binoculars I think I still see one horse on the tfred hayes-2/1/2011
2767All three horses in the race plunged off the cliff and are dashed on the rocks bscaram(o)uche-2/1/2011
2766Don't feel that it's going to move big-time, either direction, before thscaram(o)uche-2/1/2011
2765That's one of those "ya'd think" situations, as in ya'd thtom pope-2/1/2011
2764Add Vivus (VVUS), apparently in sympathy with OREX, down 15% as I type. Cheers,tuck-2/1/2011
2763Orexigen (OREX), in spite of positive panel, off 71% on CRL requiring trials fortuck-2/1/2011
2762Antisoma down two thirds, as AS1413 abandoned after PIII whiffs.nigel bates-1/31/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News